R&D Briefing

CIRS RD Briefing 80 – Reimagining medicine regulatory models

This R&D Briefing summarises the outputs of breakout group discussions held during a CIRS multi-stakeholder workshop in December 2020 entitled ‘Reimagining medicine regulatory models: implementing fit-for-purpose sustainable activities for [...]

2021-05-04T14:25:25+00:00April 14th, 2021|Tags: |

CIRS RD Briefing 75 – Emergency Use Pathways (EUPs)

It has become clear that agencies have a number of pathways that can be used during public health emergencies for the authorisation of therapeutics and vaccines. Some of these [...]

2021-01-19T09:27:54+00:00May 6th, 2020|Tags: |

CIRS RD Briefing 74 – OpERA programme

CIRS has collected regulatory assessment data for over 20 years, initially with ICH and ICH-observing countries. The OpERA programme, “Optimising Efficiencies in Regulatory Agencies (OpERA)”, was initiated through CIRS [...]

2021-06-07T10:56:57+00:00January 8th, 2020|Tags: , |

CIRS RD Briefing 73 – HTA outcomes 2014-18

Timely recommendation for drug reimbursement by health technology assessment (HTA) agencies is critical to ensure that patient access to medicines of therapeutic value is not delayed. As part of an [...]

2025-03-20T16:47:21+00:00July 10th, 2019|Tags: , |
Go to Top